Martina Zappa

Dr. Martina Zappa

University of Insubria, Varese, Lombardy, Italy
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 September 2021 in European Journal of Internal Medicine
Verified
Journal Article
Closed access
Fabio AngeliFabio Angeli
Fabio Angeli
MZMartina Zappa
Martina Zappa
GRGianpaolo Reboldi
Gianpaolo Reboldi
MTMonica Trapasso
Monica Trapasso
CCClaudio Cavallini
Claudio Cavallini
Paolo VerdecchiaPaolo Verdecchia
Paolo Verdecchia

22 June 2022 in European Journal of Internal Medicine
Verified
Journal Article
Closed access
Fabio AngeliFabio Angeli
Fabio Angeli
GRGianpaolo Reboldi
Gianpaolo Reboldi
MTMonica Trapasso
Monica Trapasso
MZMartina Zappa
Martina Zappa
ASAntonio Spanevello
Antonio Spanevello
Paolo VerdecchiaPaolo Verdecchia
Paolo Verdecchia

1 August 2021 in European Journal of Internal Medicine
Verified
Journal Article
Closed access
MZMartina Zappa
Martina Zappa
Paolo VerdecchiaPaolo Verdecchia
Paolo Verdecchia
ASAntonio Spanevello
Antonio Spanevello
DVDina Visca
Dina Visca
Fabio AngeliFabio Angeli
Fabio Angeli

Verified
Journal Article
Open access
PDF file
LPLaura Pini
Laura Pini
DBDiego Bagnasco
Diego Bagnasco
Bianca BeghèBianca Beghè
Bianca Beghè
FBFulvio Braido
Fulvio Braido
PCPaolo Cameli
Paolo Cameli
OGon behalf of the SANI Study Group
on behalf of the SANI Study Group
Background: Benralizumab has been shown to restore good control of severe eosinophilic asthma (SEA). Robust data on benralizumab effectiveness over periods longer than 2 years are scarce. Methods: This retrospective multicentric study was conducted on 108 Italian SEA patients treated with benralizumab for up to 36 months. Partial and complete clinical remission (CR) were assessed. Data were analyzed with descriptive statistics or using linear, logistic, and negative binomial mixed-effect regression models. Results: At 36 months, benralizumab reduced the exacerbation rate by 89% and increased the forced expiratory volume in 1 second (FEV1) (+440 mL at 36 months, p < 0.0001). Benralizumab improved asthma control as well as sinonasal symptoms in patients with chronic rhinosinusitis with nasal polyposis (CRSwNP). Up to 93.33% of patients either reduced or discontinued OCS; benralizumab also decreased ICS use and other asthma medications. Overall, 84.31% of patients achieved partial or complete CR. Conclusions: Benralizumab improved asthma and sinonasal outcomes up to 36 months. These findings support the potential of benralizumab to induce CR, emphasizing its role as a disease-modifying anti-asthmatic drug for the management of SEA. Further research is warranted to expand these findings by minimizing data loss and assessing benralizumab’s long-term safety.

Fabio AngeliFabio Angeli
Fabio Angeli
GRGianpaolo Reboldi
Gianpaolo Reboldi
MTMonica Trapasso
Monica Trapasso
GSGabriella Santilli
Gabriella Santilli
MZMartina Zappa
Martina Zappa
Paolo VerdecchiaPaolo Verdecchia
Paolo Verdecchia
Coronavirus disease 2019 (COVID-19) vaccines proved a strong clinical efficacy against symptomatic or moderate/severe COVID-19 and are considered the most promising approach for curbing the pandemic. However, some questions regarding the safety of COVID-19 vaccines have been recently raised. Among adverse events to vaccines and despite a lack of signal during phase III clinical trials, an increase in blood pressure (BP) after COVID-19 vaccination has been reported as a potential adverse reaction. We systematically analyze this topic and undertook a meta-analysis of available data to estimate the proportion of patients with abnormal BP or raise in BP after vaccination. Six studies entered the final analysis. Overall, studies accrued 357,387 subjects with 13,444 events of abnormal or increased BP. After exclusion of outlier studies, the pooled estimated proportion of abnormal/increased BP after vaccination was 3.20% (95% CI: 1.62–6.21). Proportions of cases of stage III hypertension or hypertensive urgencies and emergencies was 0.6% (95% CI: 0.1% to 5.1%). In conclusion, abnormal BP is not rare after COVID-19 vaccination, but the basic mechanisms of this phenomenon are still unclear and require further research.

1 January 2025 in Therapeutic Advances in Respiratory Disease
Verified
Journal Article
Open access
MVMarco Vanetti
Marco Vanetti
Dina ViscaDina Visca
Dina Visca
FAFrancesco Ardesi
Francesco Ardesi
MZMartina Zappa
Martina Zappa
PPPatrizia Pignatti
Patrizia Pignatti
ASAntonio Spanevello
Antonio Spanevello
Chronic Obstructive Pulmonary Disease (COPD) is a heterogeneous lung condition characterised by chronic respiratory symptoms, fixed airway obstruction and persistent inflammation that leads to a progressive airflow limitation. Although COPD has traditionally been linked to neutrophilic inflammation, recent studies have identified a subset of patients – approximately 20%–40% – with elevated eosinophil levels in blood and sputum. Emerging evidence suggests that eosinophilic inflammation has a pivotal role in a subset of COPD patients and may influence disease progression, exacerbation frequency and therapeutic responses. This narrative review provides a comprehensive analysis of the role of eosinophils in COPD with particular attention to their role as biomarkers in blood and sputum. We evaluate the prevalence of eosinophilic inflammation in COPD exanimating different thresholds used in blood and in sputum to define it. In addition, we focus on eosinophilic COPD phenotype as a treatable trait, emphasising recent evidence that supports the effectiveness of biological target therapy.